Search Results
May 14, 2026, 11:48 ET Datar Cancer Genetics Receives Landmark US FDA Clearance for CellDx-Tissue, a Comprehensive Genomic Profiling Assay for Solid Tumors Using DNA + RNA
Clearance Recognises CellDx-Tissue's Dual-Analyte DNA and RNA Workflow Across 517 Cancer-Associated Genes, with ALK, RET and ROS1 Fusion Calls on RNA-Level EvidenceNASHIK, India, May 14, 2026 /PRNewswire/
More news about: Datar Cancer Genetics
May 14, 2026, 11:39 ET Datar Cancer Genetics Receives Landmark US FDA Clearance for CellDx-Tissue, a Comprehensive Genomic Profiling Assay for Solid Tumors Using DNA + RNA
Clearance Recognises CellDx-Tissue's Dual-Analyte DNA and RNA Workflow Across 517 Cancer-Associated Genes, with ALK, RET and ROS1 Fusion Calls on RNA-Level EvidenceNASHIK, India, May 14, 2026 /PRNewswire/
More news about: Datar Cancer Genetics
May 14, 2026, 08:00 ET CREATE Medicines Announces $122 Million Series B Financing to Advance In Vivo CAR Pipeline in Autoimmune Disease and Oncology
Collectively, these programs exemplify CREATE's iterative platform that integrates clinically validated CAR architectures, optimized RNA design, and targeted delivery technologies with deep expertise across clinical development, translational medicine, manufacturing, and regulatory execution."CREATE
More news about: CREATE Medicines, Inc.
May 14, 2026, 08:00 ET Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting
quantification of β- and α-cell mass, electron microscopy (EM), and islets were isolated for ex-vivo glucose-stimulated insulin secretion (GSIS) and single-cell RNA sequencing. The results at four weeks showed major improvements in the control of diabetes.At four weeks after surgery, ex-vivo GSIS showed that
More news about: Genprex, Inc.
May 13, 2026, 21:41 ET 晶泰生態賦能項目劑泰科技成功IPO，產業稀缺生態平台全面邁入價值兌現期
時代的「全球科學基礎設施」，通過不斷復用算法與自動化實驗集群，沉澱跨學科真實數據，平台能夠持續、規模化地驅動源頭創新，挑戰兼具高難度與高回報的產業命題。目前，這套底層平台已展現出跨模態、跨賽道的高度可遷移性。在小分子、抗體、多肽、核酸、分子膠等廣泛領域，晶泰的系統賦能能力正加速轉化為被投資企業的真實成果：助力希格生科（AI+類器官新藥發現）、萊芒生物（超低劑量新一代細胞治療）、默達生物（免疫代謝機制下的新一代平台型藥物)、溪礫科技（AI+RNA 靶向罕見病與自免疾病）等管線公司的多款創新藥實現臨床轉化；賦能耀速科技（AI+器官芯片）、深度原理（AI
More news about: 晶泰科技
May 13, 2026, 06:50 ET Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results
program, as part of a broader strategic focus on rare renal indications.The Company also continues to collaborate with Secarna to identify RNA–based therapeutic candidates that may complement its proprietary ProCellEx® platform.Financial Outlook: Building Durable Growth
More news about: Protalix BioTherapeutics, Inc.
May 12, 2026, 16:10 ET Ribo gibt strategische Zusammenarbeit mit Insilico Medicine bekannt, um die Entwicklung von siRNA-Medikamenten mithilfe von KI voranzutreiben
ist ein weltweit tätiges biopharmazeutisches Unternehmen, das sich der Entwicklung und Vermarktung von Therapeutika auf Basis kleiner interferierender RNA (siRNA) widmet. Auf der Grundlage seiner selbst entwickelten siRNA-Technologieplattform hat Ribo eine umfassende und differenzierte Produktpipeline aufgebaut,
More news about: Suzhou Ribo Life Science Co., Ltd.
May 12, 2026, 08:30 ET Insilico Medicine and Ribo Enter Strategic Collaboration Agreement: Leveraging AI Platform and Automated Lab for End-to-End Empowerment of RNA Interference and Oligonucleotide Therapeutics Development
RiboSuzhou Ribo Life Science Co., Ltd. is a global biopharmaceutical company dedicated to the development and commercialization of small interfering RNA (siRNA) therapeutics. Leveraging its self-developed siRNA technology platform, Ribo has established a comprehensive and differentiated product pipeline
More news about: Insilico Medicine
May 12, 2026, 08:30 ET Ribo Announces Strategic Collaboration with Insilico Medicine to Accelerate siRNA Drug Development Driven by AI
RiboSuzhou Ribo Life Science Co., Ltd. is a global biopharmaceutical company dedicated to the development and commercialization of small interfering RNA (siRNA) therapeutics. Leveraging its self-developed siRNA technology platform, Ribo has established a comprehensive and differentiated product pipeline
More news about: Suzhou Ribo Life Science Co., Ltd.
May 12, 2026, 07:00 ET Castle Biosciences' AdvanceAD-Tx™ Test Receives 2026 MedTech Breakthrough Award for Genomics Innovation
(GEP) test designed to guide systemic treatment decisions for patients aged 12 years and older with moderate-to-severe atopic dermatitis (AD). Using RNA expression data from lesional skin scraping samples—no biopsy required—the test evaluates 487 genes across 12 inflammatory and cutaneous biology pathways
More news about: Castle Biosciences, Inc.
May 12, 2026, 03:04 ET ACROBiosystems Innovation Day Lands in Zurich: Top Minds Unite to Explore Biotech Frontiers
ADC Production", they presented a patented technology that enhances enzyme stability and reusability. They presented two case studies: immobilizing T7 RNA polymerase for semi-continuous in vitro transcription (IVT) systems, demonstrating retained activity and reuse potential; and immobilizing sortase for
More news about: ACROBiosystems Group
May 12, 2026, 03:00 ET SkylineDx to Showcase New Cutaneous Squamous Cell Carcinoma Findings at 83rd Society for Investigative Dermatology Annual Meeting
metastatic disease, four national databases in the Netherlands were integrated to assemble a cohort of clinically annotated tumors linked to outcome. RNA-sequencing was performed on 366 tumors, and whole-exome sequencing was performed on 147 tumors. Findings provide a new, more detailed molecular picture
More news about: SkylineDx
May 12, 2026, 02:59 ET DNA 'barcodes' help NUS researchers pinpoint gold nanoparticles that can strike cancer at its power source
cubic gold nanoparticle, achieved 99 per cent tumour regression in preclinical studies when used in a combined treatment involving mitochondria-targeted RNA therapy and mild photothermal therapy.Led by Assistant Professor Andy Tay from the Department
More news about: National University of Singapore
May 11, 2026, 13:41 ET New AI tool predicts how cells choose their future, helping uncover hidden drivers of development
maps of development. RNA velocity methods can help researchers estimate how cells move through developmental landscapes, while gene regulatory network approaches can identify relationships among genes. But those methods have typically been used in parallel rather than together. RNA velocity methods often
More news about: Stowers Institute for Medical Research
May 11, 2026, 12:41 ET DNA Polymerase Market to Reach USD 725.8 Million by 2035 as Molecular Diagnostics and High-Fidelity Enzymes Accelerate Precision Genomics
CorporationRelated ReportsDNA/RNA Extraction Market: https://www.futuremarketinsights.com/reports/dna-rna-extraction-marketDNA Diagnostics Market:
More news about: Future Market Insights
May 11, 2026, 06:00 ET Partner Therapeutics Announces FDA Approval of BIZENGRI® (Zenocutuzumab-zbco) for NRG1 Fusion-Positive Cholangiocarcinoma Following Receipt of FDA Commissioner's National Priority Voucher
targeted treatment option in this setting. These data further highlight the essential role of comprehensive molecular testing, particularly tissue-based RNA-based sequencing, to reliably detect gene fusions such as NRG1 and ensure patients are appropriately identified for targeted therapy."—
More news about: Partner Therapeutics, Inc.
May 08, 2026, 16:05 ET Caris Life Sciences Submits Application to New York State Department of Health for Caris Assure Blood‑Based Testing Authorization
minimally invasive blood sample. Caris Assure uses circulating nucleic acids sequencing (cNAS) to analyze the whole exome (DNA) and whole transcriptome (RNA) of 22,000 genes. This comprehensive test identifies tumor alterations, clonal hematopoiesis (CH) and inherited variants, pharmacogenomic alterations,
More news about: Caris Life Sciences
May 08, 2026, 11:44 ET Advaita Bio představuje iSCanGuide™: Integrovanou analýzu jednobuněčné a prostorové transkriptomiky využívající infrastrukturu s GPU akcelerací
Xenium. Vizualizujte prostorové rozložení buněk a identifikujte prostorově variabilní geny – to vše ve stejném prostředí, které se používá pro sekvenování RNA jednotlivých buněk, bez nutnosti exportu dat.Integrované frameworky: Přímé napojení na proprietární metodiku Impact Analysis v iPathwayGuide™
More news about: Advaita Bio
May 08, 2026, 09:00 ET Co-Diagnostics Joint Venture CoMira Finalizes Lease Agreement for Manufacturing Facility in Saudi Arabia's Sudair Industrial City
technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory
More news about: Co-Diagnostics
May 08, 2026, 04:17 ET Rznomics Announces U.S. FDA Regenerative Medicine Advanced Therapy Designation Granted to 'RZ-001' for Hepatocellular Carcinoma
rates, with trans-splicing ribozyme-based RNA editing platformSEOUL, South Korea, May 8, 2026 /PRNewswire/ -- Rznomics a biopharmaceutical company specializing in RNA-based gene therapeutics, announced today that
More news about: Rznomics
May 07, 2026, 14:40 ET Franklin Biolabs and RareMoon Consulting announce a Strategic Partnership to integrate Preclinical Development with Regulatory Expertise
its expanded capabilities.About Franklin BiolabsFranklin Biolabs is a fully integrated preclinical CRO accelerating cell, gene, RNA, and biologics therapies from discovery to commercialization. Headquartered in Philadelphia and founded by gene therapy pioneer Dr. Jim Wilson, the company
More news about: Franklin Biolabs
May 07, 2026, 12:08 ET Advaita Bio wprowadza iSCanGuide™: ujednoliconą analizę transkryptomiki pojedynczych komórek i przestrzennej opartą na infrastrukturze akcelerowanej przez GPU
Wizualizacja przestrzennych rozmieszczeń komórek i identyfikacja genów zmiennych przestrzennie - wszystko w tym samym środowisku wykorzystywanym do analizy RNA-seq pojedynczych komórek, bez konieczności eksportowania danych.- Zintegrowane ramy: bezpośrednia integracja z autorską
More news about: Advaita Bio
May 07, 2026, 12:04 ET Advaita Bio spúšťa iSCanGuide™: platformu pre analýzu jednobunkových a priestorových transkriptomických dát s akceleráciou GPU
Vizualizuje priestorové rozloženie buniek a identifikuje priestorovo variabilné gény – to všetko v rovnakom prostredí používanom pre jednobunkové RNA-seq, bez potreby exportu dát.Integrované rámce: priamo napojené na proprietárnu metodológiu Impact Analysis platformy iPathwayGuide™ pre
More news about: Advaita Bio
May 07, 2026, 12:02 ET Advaita Bio запускает iSCanGuide™ -- единую платформу для анализа одноклеточной и пространственной транскриптомики на базе инфраструктуры с GPU-ускорением
пространственное распределение клеток и выявлять пространственно вариабельные гены в той же среде, что используется для секвенирования одноклеточной РНК (RNA-seq), без необходимости экспорта данных.Интегрированные аналитические механизмы: непосредственная интеграция iSCanGuide с собственной методологией
More news about: Advaita Bio
May 07, 2026, 10:54 ET Advaita Bio bringt iSCanGuide™ auf den Markt: Vereinheitlichte Analyse für Einzelzell-Transkriptomik und räumliche Transkriptomik, gestützt auf GPU-beschleunigte Infrastruktur
Räumliche Zellverteilungen lassen sich visualisieren und räumlich variable Gene identifizieren, und zwar innerhalb derselben Umgebung, die für Einzelzell-RNA-seq verwendet wird, ohne dass ein Datenexport erforderlich ist.Integrierte Rahmenwerke: Direkte Einspeisung in die firmeneigene Impact-Analysis-Methodik
More news about: Advaita Bio